Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst, Inc. received an updated ownership disclosure from investment firm Whetstone Capital Advisors, LLC and its manager David Atterbury. They report beneficial ownership of 5,782,941 shares of common stock, equal to 8.2% of the company based on 70,730,884 shares outstanding as of November 5, 2025.
The position includes 1,515,000 shares underlying long options, purchased for an aggregate of about $17.7 million using fund capital. Whetstone and Atterbury share voting and disposition power over all reported shares. They also hold 15,150 long options exercisable for 1,515,000 shares and have sold short 30,300 option contracts tied to Health Catalyst stock, all exercisable until December 18, 2026.
Health Catalyst, Inc. named Ben Albert as its new Chief Executive Officer and a director, effective February 12, 2026, as part of an accelerated succession plan for retiring CEO Dan Burton, who will move to a strategic advisor role under an expected transition agreement.
Albert, previously President and COO and former CEO/co‑founder of Upfront Healthcare, will receive a $600,000 base salary, an annual bonus target equal to 100% of salary, 465,000 RSUs, and 465,000 performance-based RSUs, along with amended vesting of 467,000 RSUs granted in 2025. The company is also reshaping governance: multiple long‑tenured directors are resigning and the Board will ultimately be reduced to five members immediately prior to the 2026 annual meeting, with Justin Spencer serving as chair and committee memberships rebalanced.
Health Catalyst, Inc. announced a leadership transition in its commercial organization. The Board of Directors determined that Kevin Freeman will cease serving as Chief Commercial Officer on February 1, 2026. The company and Mr. Freeman anticipate entering into a separation agreement and then an independent contractor agreement under which he will serve as a senior advisor starting February 2, 2026.
The separation agreement is expected to provide Mr. Freeman with separation benefits under the company’s Executive Severance Plan, in exchange for a general release of claims. The plan was previously described in the company’s definitive proxy statement filed on May 19, 2025. The filing also notes that statements about the anticipated agreements are forward-looking and subject to risks and uncertainties.
Whetstone Capital Advisors and David Atterbury have filed a Schedule 13D on Health Catalyst, Inc. They report beneficial ownership of 5,265,377 shares of common stock, or 7.4% of the company, including 1,515,000 shares issuable upon exercise of long call options. The stake was acquired for approximately $15,701,426 of fund capital.
The filing describes an active investment approach. On January 15, 2026, the reporting persons notified Health Catalyst that they intend to submit a shareholder proposal aimed at improving corporate governance at the next annual or special meeting. Proposed changes include immediate declassification of the board, majority voting standards to amend the charter and bylaws, shareholder rights to call special meetings and act by written consent, separation of the CEO and board chair roles, and term limits for directors and members of the nominating and governance committee.
The investors indicate they may continue discussions with management, the board, and other shareholders, and could increase or decrease their position or use derivatives depending on company performance, market conditions, and other investments.
Health Catalyst, Inc. received an updated ownership report showing that Whetstone Capital Advisors, LLC and David Atterbury together beneficially own 3,750,377 shares of its common stock. This stake represents 5.3% of the company’s outstanding common shares as of the reporting date.
The filing states that the reporting persons share both voting and dispositive power over all of these shares and have no sole voting or dispositive authority. They also certify that the shares were not acquired for the purpose of changing or influencing control of Health Catalyst.
Health Catalyst, Inc. filed a Form 8-K to let investors know it has released an excerpt of its preliminary, unaudited estimated 2025 financial and operational results along with forward-looking commentary. The company notes these figures may change once year-end accounting and annual audit procedures are completed, so they should be viewed as estimates rather than final results. The information is provided in an “Excerpt” attached as Exhibit 99.1 and incorporated by reference. The company also specifies that this information is being furnished, not filed, which means it is not subject to certain liability provisions under the federal securities laws unless expressly incorporated into other filings.
Health Catalyst, Inc. (HCAT) reported Q3 2025 results. Revenue was $76.3 million, essentially flat year over year. Technology revenue rose to $52.1 million while Professional services declined to $24.3 million. Operating loss widened to $17.5 million and net loss was $22.2 million, or $0.32 per share.
Year to date, revenue reached $236.5 million with a net loss of $86.9 million, including a $28.8 million goodwill impairment. Gross costs held steady overall, but operating expenses increased, notably depreciation and amortization at $12.6 million in Q3. Interest and other expense was $4.7 million in Q3, driving a larger pre‑tax loss.
Liquidity contracted: cash and cash equivalents were $40.3 million as of September 30, 2025 versus $249.6 million at year‑end, reflecting $231.9 million of debt repayment and acquisition spending in the nine‑month cash flows. Total assets were $587.1 million and total liabilities $255.2 million. Shares outstanding were 70,730,884 as of November 5, 2025.
Health Catalyst, Inc. (HCAT) reported Q3 2025 results. Revenue was $76.3 million, essentially flat year over year. Technology revenue rose to $52.1 million while Professional services declined to $24.3 million. Operating loss widened to $17.5 million and net loss was $22.2 million, or $0.32 per share.
Year to date, revenue reached $236.5 million with a net loss of $86.9 million, including a $28.8 million goodwill impairment. Gross costs held steady overall, but operating expenses increased, notably depreciation and amortization at $12.6 million in Q3. Interest and other expense was $4.7 million in Q3, driving a larger pre‑tax loss.
Liquidity contracted: cash and cash equivalents were $40.3 million as of September 30, 2025 versus $249.6 million at year‑end, reflecting $231.9 million of debt repayment and acquisition spending in the nine‑month cash flows. Total assets were $587.1 million and total liabilities $255.2 million. Shares outstanding were 70,730,884 as of November 5, 2025.
Health Catalyst, Inc. (HCAT) reported Q3 2025 results. Revenue was $76.3 million, essentially flat year over year. Technology revenue rose to $52.1 million while Professional services declined to $24.3 million. Operating loss widened to $17.5 million and net loss was $22.2 million, or $0.32 per share.
Year to date, revenue reached $236.5 million with a net loss of $86.9 million, including a $28.8 million goodwill impairment. Gross costs held steady overall, but operating expenses increased, notably depreciation and amortization at $12.6 million in Q3. Interest and other expense was $4.7 million in Q3, driving a larger pre‑tax loss.
Liquidity contracted: cash and cash equivalents were $40.3 million as of September 30, 2025 versus $249.6 million at year‑end, reflecting $231.9 million of debt repayment and acquisition spending in the nine‑month cash flows. Total assets were $587.1 million and total liabilities $255.2 million. Shares outstanding were 70,730,884 as of November 5, 2025.
Health Catalyst (HCAT) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company attached the full release and a Q3 2025 earnings summary as Exhibit 99.1 and Exhibit 99.2, respectively. The materials are being furnished under Item 2.02 and are not deemed filed under the Exchange Act.
Health Catalyst (HCAT) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company attached the full release and a Q3 2025 earnings summary as Exhibit 99.1 and Exhibit 99.2, respectively. The materials are being furnished under Item 2.02 and are not deemed filed under the Exchange Act.
Health Catalyst (HCAT) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company attached the full release and a Q3 2025 earnings summary as Exhibit 99.1 and Exhibit 99.2, respectively. The materials are being furnished under Item 2.02 and are not deemed filed under the Exchange Act.
Albert Benjamin, President and COO of Health Catalyst, Inc. (HCAT), was granted 467,000 restricted stock units (RSUs) on 09/24/2025 under the companys 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to one share of common stock. After the grant, the filing reports 577,870 shares beneficially owned by the reporting person. The RSUs vest 33.33% on September 10, 2026, with the remaining 66.67% vesting in eight equal quarterly installments thereafter.
Albert Benjamin filed an initial Form 3 reporting his beneficial ownership in Health Catalyst, Inc. (HCAT). He directly holds 92,870 common shares and 18,000 restricted stock units (RSUs) granted under the 2019 Plan that vest beginning March 1, 2026. He also reports indirect holdings of 148,198 shares via the "Benjamin Albert Declaration of Trust" and 28,697 shares via the "Albert Family Trust." The filing is signed by an attorney-in-fact on 09/26/2025.